Endo Withdraws Frova sNDA For Menstrual Migraine Prevention
This article was originally published in The Pink Sheet Daily
Executive Summary
Action comes days after former Johnson & Johnson exec Holveck takes the helm as president and CEO.
You may also be interested in...
Vernalis Restructures, Gives Up U.S. Frova Rights To Increase Cash Reserves
UK company's decision to lay off almost half its workforce, divest Parkinson's therapy Apokyn and shut down U.S. operations stems from "not approvable" letter for Frova last fall for menstrual migraine.
FDA “Not Approvable” Letter Questions Benefit Of Endo’s Frova In Menstrual Migraine
Agency indicates potential for vascular events is another reason frovatriptan is "not approvable" for short-term prevention of menstrual migraine.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.